for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Strongbridge Biopharma plc

SBBP.OQ

Latest Trade

2.68USD

Change

-0.06(-2.19%)

Volume

751,316

Today's Range

2.59

 - 

2.86

52 Week Range

2.16

 - 

6.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.74
Open
2.73
Volume
751,316
3M AVG Volume
4.24
Today's High
2.86
Today's Low
2.59
52 Week High
6.52
52 Week Low
2.16
Shares Out (MIL)
54.19
Market Cap (MIL)
148.47
Forward P/E
-2.80
Dividend (Yield %)
--

Next Event

Strongbridge Biopharma plc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Strongbridge Biopharma Announces Recorlev (Levoketoconazole) Phase 3 Sonics Data

Strongbridge Biopharma Announces Key Leadership Appointments To Support Next Stage Of Growth

Strongbridge Biopharma Reports Second Quarter 2019 Revenue Of $6.1 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Strongbridge Biopharma plc

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Industry

Biotechnology & Drugs

Contact Info

900 Northbrook Dr Ste 200

+1.610.2549200

http://www.strongbridgebio.com/

Executive Leadership

John H. Johnson

Chairman of the Board

Matthew Pauls

Chief Executive Officer, Director

Robert Matthew Lutz

Chief Financial Officer

Richard S. Kollender

Chief Operating Officer

Marcy Nanus

Vice President - Corporate Affairs

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.260

2017

-3.110

2018

0.310

2019(E)

-1.006
Price To Earnings (TTM)
3.60
Price To Sales (TTM)
7.32
Price To Book (MRQ)
1.63
Price To Cash Flow (TTM)
3.44
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
28.47
Return on Equity (TTM)
25.27

Latest News

BRIEF-Strongbridge To Host Conference Call On March 12 To Announce Fourth Quarter And Year-End 2017 Results

* STRONGBRIDGE BIOPHARMA PLC TO HOST CONFERENCE CALL ON MARCH 12, 2018 TO ANNOUNCE FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Strongbridge Biopharma Announces Pricing Of Public Offering

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

BRIEF-Strongbridge Biopharma Announces Proposed Public Offering Of 5 Mln Ordinary Shares

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF 5 MILLION ORDINARY SHARES Source text for Eikon: Further company coverage:

BRIEF-Strongbridge Biopharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For New Patent Covering RECORLEV

* STRONGBRIDGE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR NEW PATENT COVERING RECORLEV™ (LEVOKETOCONAZOLE) FOR THE TREATMENT OF CUSHING’S SYNDROME

BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

BRIEF-Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis

* STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS

BRIEF-Strongbridge Biopharma Q3 loss per share $0.98

* Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results

BRIEF-Strongbridge Biopharma Plc announces proposed public offering of ordinary shares

* Strongbridge Biopharma Plc announces proposed public offering of ordinary shares

BRIEF-Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma

* Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma Plc as of Sept 12, 2017 - SEC filing Source text: (http://bit.ly/2xlELBz) Further company coverage:

BRIEF-Strongbridge Biopharma secures $53 mln financing from CRG

* Strongbridge Biopharma Plc secures $53 million financing from crg

BRIEF-Strongbridge Biopharma Plc posts Q1 loss per share $0.83

* Strongbridge Biopharma Plc provides corporate update and reports first quarter 2017 financial results

BRIEF-Strongbridge Biopharma files for mixed shelf offering of up to $150 mln

* Strongbridge Biopharma Plc files for mixed shelf offering of up to $150 million - sec filing Source text: (http://bit.ly/2pdCALq) Further company coverage:

BRIEF-Strongbridge Biopharma Plc phase 3 sonics study more than 80 pct enrolled

* Strongbridge Biopharma Plc provides corporate update and reports full-year 2016 financial results

BRIEF-Strongbridge Biopharma files for proposed resale of up to 28.3 mln shares

* Files for proposed resale or other disposition of up to 28.3 million ordinary shares by selling shareholders

BRIEF-Vivo Capital LLC reports 8.52 pct passive stake in Strongbridge Biopharma- SEC filing

* Vivo Capital VIII LLC reports 8.52 percent passive stake in Strongbridge Biopharma Plc as of Dec 28, 2016 - sec filing Source text for Eikon: Further company coverage:

BRIEF-Strongbridge Biopharma announces appointment of Jeffrey Sherman to board of directors

* Strongbridge Biopharma Plc announces appointment of Jeffrey W. Sherman, M.D., FACP, to board of directors Source text for Eikon: Further company coverage:

BRIEF-Storebrand Asset Management reports 5.01 pct passive stake in Strongbridge Biopharma

* Storebrand Asset Management AS reports 5.01 pct passive stake in Strongbridge Biopharma Plc as of Sept 20 - SEC filing Source text (http://bit.ly/2cEnm8P) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up